Cargando…
Vulnerabilities in Older Patients when Cancer Treatment is Initiated: Does a Cognitive Impairment Impact the Two-Year Survival?
INTRODUCTION: Dementia is a known predictor of shorter survival times in older cancer patients. However, no empirical evidence is available to determine how much a cognitive impairment shortens survival in older patients when cancer treatment is initiated. PURPOSE: To longitudinally investigate how...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968794/ https://www.ncbi.nlm.nih.gov/pubmed/27479248 http://dx.doi.org/10.1371/journal.pone.0159734 |
_version_ | 1782445704933801984 |
---|---|
author | Libert, Yves Dubruille, Stéphanie Borghgraef, Cindy Etienne, Anne-Marie Merckaert, Isabelle Paesmans, Marianne Reynaert, Christine Roos, Myriam Slachmuylder, Jean-Louis Vandenbossche, Sandrine Bron, Dominique Razavi, Darius |
author_facet | Libert, Yves Dubruille, Stéphanie Borghgraef, Cindy Etienne, Anne-Marie Merckaert, Isabelle Paesmans, Marianne Reynaert, Christine Roos, Myriam Slachmuylder, Jean-Louis Vandenbossche, Sandrine Bron, Dominique Razavi, Darius |
author_sort | Libert, Yves |
collection | PubMed |
description | INTRODUCTION: Dementia is a known predictor of shorter survival times in older cancer patients. However, no empirical evidence is available to determine how much a cognitive impairment shortens survival in older patients when cancer treatment is initiated. PURPOSE: To longitudinally investigate how much a cognitive impairment detected at the initiation of cancer treatment influences survival of older patients during a two-year follow-up duration and to compare the predictive value of a cognitive impairment on patients survival with the predictive value of other vulnerabilities associated with older age. METHODS: Three hundred and fifty-seven consecutive patients (≥65 years old) admitted for breast, prostate, or colorectal cancer surgeries were prospectively recruited. A cognitive impairment was assessed with the Montreal Cognitive Assessment (MoCA<26). Socio-demographic, disease-related, and geriatric vulnerabilities were assessed using validated tools. Univariate and subsequent multivariate Cox proportional hazards models stratified for diagnosis (breast/prostate cancer versus colorectal cancer) and disease status (metastatic versus non-metastatic) were used. RESULTS: A cognitive impairment was detected in 46% (n = 163) of patients. Survival was significantly influenced by a cognitive impairment (HR = 6.13; 95% confidence interval [CI] = 2.07–18.09; p = 0.001), a loss in instrumental autonomy (IADL ≤7) (HR = 3.06; 95% CI = 1.31–7.11; p = 0.009) and fatigue (Mob-T<5) (HR = 5.98; 95% CI = 2.47–14.44; p <0.001). CONCLUSIONS: During the two years following cancer treatment initiation, older patients with a cognitive impairment were up to six times more likely to die than patients without. Older patients should be screened for cognitive impairments at cancer treatment initiation to enable interventions to reduce morbidity and mortality. Further studies should address processes underlying the relationship between cognitive impairments and an increased risk of dying in older cancer patients. |
format | Online Article Text |
id | pubmed-4968794 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-49687942016-08-18 Vulnerabilities in Older Patients when Cancer Treatment is Initiated: Does a Cognitive Impairment Impact the Two-Year Survival? Libert, Yves Dubruille, Stéphanie Borghgraef, Cindy Etienne, Anne-Marie Merckaert, Isabelle Paesmans, Marianne Reynaert, Christine Roos, Myriam Slachmuylder, Jean-Louis Vandenbossche, Sandrine Bron, Dominique Razavi, Darius PLoS One Research Article INTRODUCTION: Dementia is a known predictor of shorter survival times in older cancer patients. However, no empirical evidence is available to determine how much a cognitive impairment shortens survival in older patients when cancer treatment is initiated. PURPOSE: To longitudinally investigate how much a cognitive impairment detected at the initiation of cancer treatment influences survival of older patients during a two-year follow-up duration and to compare the predictive value of a cognitive impairment on patients survival with the predictive value of other vulnerabilities associated with older age. METHODS: Three hundred and fifty-seven consecutive patients (≥65 years old) admitted for breast, prostate, or colorectal cancer surgeries were prospectively recruited. A cognitive impairment was assessed with the Montreal Cognitive Assessment (MoCA<26). Socio-demographic, disease-related, and geriatric vulnerabilities were assessed using validated tools. Univariate and subsequent multivariate Cox proportional hazards models stratified for diagnosis (breast/prostate cancer versus colorectal cancer) and disease status (metastatic versus non-metastatic) were used. RESULTS: A cognitive impairment was detected in 46% (n = 163) of patients. Survival was significantly influenced by a cognitive impairment (HR = 6.13; 95% confidence interval [CI] = 2.07–18.09; p = 0.001), a loss in instrumental autonomy (IADL ≤7) (HR = 3.06; 95% CI = 1.31–7.11; p = 0.009) and fatigue (Mob-T<5) (HR = 5.98; 95% CI = 2.47–14.44; p <0.001). CONCLUSIONS: During the two years following cancer treatment initiation, older patients with a cognitive impairment were up to six times more likely to die than patients without. Older patients should be screened for cognitive impairments at cancer treatment initiation to enable interventions to reduce morbidity and mortality. Further studies should address processes underlying the relationship between cognitive impairments and an increased risk of dying in older cancer patients. Public Library of Science 2016-08-01 /pmc/articles/PMC4968794/ /pubmed/27479248 http://dx.doi.org/10.1371/journal.pone.0159734 Text en © 2016 Libert et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Libert, Yves Dubruille, Stéphanie Borghgraef, Cindy Etienne, Anne-Marie Merckaert, Isabelle Paesmans, Marianne Reynaert, Christine Roos, Myriam Slachmuylder, Jean-Louis Vandenbossche, Sandrine Bron, Dominique Razavi, Darius Vulnerabilities in Older Patients when Cancer Treatment is Initiated: Does a Cognitive Impairment Impact the Two-Year Survival? |
title | Vulnerabilities in Older Patients when Cancer Treatment is Initiated: Does a Cognitive Impairment Impact the Two-Year Survival? |
title_full | Vulnerabilities in Older Patients when Cancer Treatment is Initiated: Does a Cognitive Impairment Impact the Two-Year Survival? |
title_fullStr | Vulnerabilities in Older Patients when Cancer Treatment is Initiated: Does a Cognitive Impairment Impact the Two-Year Survival? |
title_full_unstemmed | Vulnerabilities in Older Patients when Cancer Treatment is Initiated: Does a Cognitive Impairment Impact the Two-Year Survival? |
title_short | Vulnerabilities in Older Patients when Cancer Treatment is Initiated: Does a Cognitive Impairment Impact the Two-Year Survival? |
title_sort | vulnerabilities in older patients when cancer treatment is initiated: does a cognitive impairment impact the two-year survival? |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968794/ https://www.ncbi.nlm.nih.gov/pubmed/27479248 http://dx.doi.org/10.1371/journal.pone.0159734 |
work_keys_str_mv | AT libertyves vulnerabilitiesinolderpatientswhencancertreatmentisinitiateddoesacognitiveimpairmentimpactthetwoyearsurvival AT dubruillestephanie vulnerabilitiesinolderpatientswhencancertreatmentisinitiateddoesacognitiveimpairmentimpactthetwoyearsurvival AT borghgraefcindy vulnerabilitiesinolderpatientswhencancertreatmentisinitiateddoesacognitiveimpairmentimpactthetwoyearsurvival AT etienneannemarie vulnerabilitiesinolderpatientswhencancertreatmentisinitiateddoesacognitiveimpairmentimpactthetwoyearsurvival AT merckaertisabelle vulnerabilitiesinolderpatientswhencancertreatmentisinitiateddoesacognitiveimpairmentimpactthetwoyearsurvival AT paesmansmarianne vulnerabilitiesinolderpatientswhencancertreatmentisinitiateddoesacognitiveimpairmentimpactthetwoyearsurvival AT reynaertchristine vulnerabilitiesinolderpatientswhencancertreatmentisinitiateddoesacognitiveimpairmentimpactthetwoyearsurvival AT roosmyriam vulnerabilitiesinolderpatientswhencancertreatmentisinitiateddoesacognitiveimpairmentimpactthetwoyearsurvival AT slachmuylderjeanlouis vulnerabilitiesinolderpatientswhencancertreatmentisinitiateddoesacognitiveimpairmentimpactthetwoyearsurvival AT vandenbosschesandrine vulnerabilitiesinolderpatientswhencancertreatmentisinitiateddoesacognitiveimpairmentimpactthetwoyearsurvival AT brondominique vulnerabilitiesinolderpatientswhencancertreatmentisinitiateddoesacognitiveimpairmentimpactthetwoyearsurvival AT razavidarius vulnerabilitiesinolderpatientswhencancertreatmentisinitiateddoesacognitiveimpairmentimpactthetwoyearsurvival |